AZD4045
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 28, 2026
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=101 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2029 ➔ Mar 2031 | Trial primary completion date: Oct 2029 ➔ Mar 2031
Enrollment open • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology
July 03, 2026
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1/2 | N=101 | Not yet recruiting | Sponsor: AstraZeneca
New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 2
Of
2
Go to page
1